Recent developments in nanoparticles for the treatment of diabetes

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(1):S55–S60.
   PubMedGoogle Scholar
• Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus—a devastating metabolic disorder. AJBPS. 2015;4(40):1–7. doi: 10.15272/ajbps.v4i40.645.
   Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and ­projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global etiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi: 10.1038/nrendo.2017.151.
   PubMed Web of Science ®Google Scholar
• Sarkar BK, Akter R, Das J, et al. Diabetes mellitus: a comprehensive review. J Pharmacog Phytochem. 2019;8(6):2362–2371.
   Google Scholar
• Sivieri K, de Oliveira SM, de Souza Marquez A, et al. Insights on β-glucan as a prebiotic coadjuvant in the treatment of diabetes mellitus: a review. Food Hydrocol Health. 2022;2:100056. doi: 10.1016/j.fhfh.2022.100056.
   Google Scholar
• Yeung AW, Tzvetkov NT, Durazzo A, et al. Natural products in diabetes research: quantitative literature analysis. Nat Prod Res. 2021;35(24):5813–5827. doi: 10.1080/14786419.2020.1821019.
   PubMed Web of Science ®Google Scholar
• Sathasivampillai SV, Rajamanoharan PR, Munday M, et al. Plants used to treat diabetes in Sri Lankan siddha medicine—an ethnopharmacological review of historical and modern sources. J Ethnopharmacol. 2017;198:531–599. doi: 10.1016/j.jep.2016.07.053.
   PubMed Web of Science ®Google Scholar
• Harsoliya MS, Patel VM, Modasiya M. Recent advances & applications of nanotechnology in diabetes. Int J Pharm Biol Arch. 2012;3:255–261.
   Google Scholar
• Mohanraj VJ, Chen YJ. Nanoparticles-a review. Trop J Pharm Res. 2007;5(1):561–573. doi: 10.4314/tjpr.v5i1.14634.
   Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (taxol®): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86(1):33–48. doi: 10.1016/S0168-3659(02)00320-6.
   PubMed Web of Science ®Google Scholar
• Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6(4):319–327. doi: 10.1016/S1359-0286(02)00117-1.
   Web of Science ®Google Scholar
• Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64(12):1292–1309. doi: 10.1016/j.addr.2012.01.016.
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2007;96(2):203–209. doi: 10.1002/bit.21301.
   PubMed Web of Science ®Google Scholar
• Zhang J, Saltzman M. Engineering biodegradable nanoparticles for drug and gene delivery. Chem Eng Prog. 2013;109(3):25.
   PubMed Web of Science ®Google Scholar
• Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target. 2007;15(3):163–183. doi: 10.1080/10611860701231810.
   PubMed Web of Science ®Google Scholar
• Onoue S, Yamada S, Chan HK. Nano drugs: pharmacokinetics and safety. Int J Nanomedicine. 2014;9:1025–1037. doi: 10.2147/IJN.S38378.
   PubMed Web of Science ®Google Scholar
• Mu Q, Jiang G, Chen L, et al. Chemical basis of interactions between engineered nanoparticles and biological systems. Chem Rev. 2014;114(15):7740–7781. doi: 10.1021/cr400295a.
   PubMed Web of Science ®Google Scholar
• Park HS, Nam SH, Kim J, et al. Clear-cut observation of clearance of sustainable upconverting nanoparticles from the lymphatic system of small living mice. Sci Rep. 2016;6(1):27407. doi: 10.1038/srep27407.
   PubMedGoogle Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515. doi: 10.1021/mp800051m.
   PubMed Web of Science ®Google Scholar
• McMillan J, Batrakova E, Gendelman HE. Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci. 2011;104:563–601. doi: 10.1016/B978-0-12-416020-0.00014-0.
   PubMed Web of Science ®Google Scholar
• Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2(4):MR17–71. doi: 10.1116/1.2815690.
   PubMed Web of Science ®Google Scholar
• Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci. 2008;97(9):3518–3590. doi: 10.1002/jps.21270.
   PubMed Web of Science ®Google Scholar
• Bantz C, Koshkina O, Lang T, et al. The surface properties of nanoparticles determine the agglomeration state and the size of the particles under physiological conditions. Beilstein J Nanotechnol. 2014;5(1):1774–1786. doi: 10.3762/bjnano.5.188.
   PubMedGoogle Scholar
• Kou L, Sun J, Zhai Y, et al. The endocytosis and intracellular fate of nanomedicines: implication for rational design. Asian J Pharm Sci. 2013;8(1):1–10. doi: 10.1016/j.ajps.2013.07.001.
   Google Scholar
• Sykes EA, Dai Q, Sarsons CD, et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci U S A. 2016;113(9):E1142–E1151. doi: 10.1073/pnas.1521265113.
   PubMed Web of Science ®Google Scholar
• Son GH, Lee BJ, Cho CW. Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. J Pharmaceu Invest. 2017;47(4):287–296. doi: 10.1007/s40005-017-0320-1.
   Google Scholar
• Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015;125:75–84. doi: 10.1016/j.ces.2014.08.046.
   PubMed Web of Science ®Google Scholar
• Wong CY, Al-Salami H, Dass CR. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release. 2017;264:247–275. doi: 10.1016/j.jconrel.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Gedawy A, Martinez J, Al-Salami H, et al. Oral insulin delivery: existing barriers and current counter-strategies. J Pharm Pharmacol. 2018;70(2):197–213. doi: 10.1111/jphp.12852.
   PubMed Web of Science ®Google Scholar
• Wong CY, Martinez J, Dass CR. Oral delivery of insulin for the treatment of diabetes: status quo, challenges, and opportunities. J Pharm Pharmacol. 2016;68(9):1093–1108. doi: 10.1111/jphp.12607.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen CH, Lin ZC, et al. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017;25(2):219–234. doi: 10.1016/j.jfda.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Garg T, Murthy RS, et al. Recent approaches of lipid-based delivery system for lymphatic targeting via the oral route. J Drug Target. 2014;22(10):871–882. doi: 10.3109/1061186X.2014.950664.
   PubMed Web of Science ®Google Scholar
• Jose S, Fangueiro JF, Smitha J, et al. Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Eur J Med Chem. 2013;60:249–253. doi: 10.1016/j.ejmech.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Sharma DK, Pattnaik G, Behera A. Development and in-vitro, in-vivo evaluation of pioglitazone-loaded polymeric nanoparticles using Central composite design surface response methodology. OpenNano. 2023;11:100141. doi: 10.1016/j.onano.2023.100141.
   Google Scholar
• Andreani T, Fangueiro JF, Severino P, et al. The influence of polysaccharide coating on the physicochemical parameters and cytotoxicity of silica nanoparticles for hydrophilic biomolecules delivery. Nanomaterials (Basel). 2019;9(8):1081. doi: 10.3390/nano9081081.
   PubMedGoogle Scholar
• Li X, Guo S, Zhu C, et al. Intestinal mucosa permeability following oral insulin delivery using core-shell corona ­nanolipoparticles. Biomaterials. 2013;34(37):9678–9687. doi: 10.1016/j.biomaterials.2013.08.048.
   PubMed Web of Science ®Google Scholar
• Sonaje K, Lin YH, Juang JH, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 2009;30(12):2329–2339. doi: 10.1016/j.biomaterials.2008.12.066.
   PubMed Web of Science ®Google Scholar
• Tahtat D, Mahlous M, Benamer S, et al. Oral delivery of insulin from alginate/chitosan crosslinked by glutaraldehyde. Int J Biol Macromol. 2013;58:160–168. doi: 10.1016/j.ijbiomac.2013.03.064.
   PubMed Web of Science ®Google Scholar
• Hu Q, Luo Y. Recent advances of polysaccharide-based nanoparticles for oral insulin delivery. Int J Biol Macromol. 2018;120(Pt A):775–782. doi: 10.1016/j.ijbiomac.2018.08.152.
   PubMedGoogle Scholar
• Burova TV, Grinberg NV, Tur DR, et al. Ternary interpolyelectrolyte complexes insulin-poly (methylaminophosphazene)-dextran sulfate for oral delivery of insulin. Langmuir. 2013;29(7):2273–2281. doi: 10.1021/la303860t.
   PubMed Web of Science ®Google Scholar
• Silva AM, Alvarado HL, Abrego G, et al. In vitro cytotoxicity of oleanolic/ursolic acids-loaded in PLGA nanoparticles in different cell lines. Pharmaceutics. 2019;11(8):362. doi: 10.3390/pharmaceutics11080362.
   PubMed Web of Science ®Google Scholar
• Sun S, Liang N, Piao H, et al. Insulin-SO (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J Microencapsul. 2010;27(6):471–478. doi: 10.3109/02652040903515490.
   PubMed Web of Science ®Google Scholar
• Kamei N, Morishita M, Eda Y, et al. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release. 2008;132(1):21–25. doi: 10.1016/j.jconrel.2008.08.001.
   PubMed Web of Science ®Google Scholar
• Thompson C, Cheng WP, Gadad P, et al. Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by caco-2 cells—towards oral insulin. Pharm Res. 2011;28(4):886–896. doi: 10.1007/s11095-010-0345-x.
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med. 2013;5(213):213ra167. doi: 10.1126/scitranslmed.3007049.
   PubMed Web of Science ®Google Scholar
• Shan W, Zhu X, Tao W, et al. Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers. ACS Appl Mater Interf. 2016;8(38):25444–25453. doi: 10.1021/acsami.6b08183.
   PubMed Web of Science ®Google Scholar
• Chen S, Guo F, Deng T, et al. Eudragit S100-coated chitosan nanoparticles co-loading tat for enhanced oral colon absorption of insulin. Aaps Pharmscitech. 2017;18(4):1277–1287. doi: 10.1208/s12249-016-0594-z.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Gorain B, Low SY, et al. Nanotechnology-based approaches for anti-diabetic drug delivery. Diabetes Res Clin Pract. 2018;136:52–77. doi: 10.1016/j.diabres.2017.11.018.
   PubMed Web of Science ®Google Scholar
• Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv. 2013;20(3–4):120–126. doi: 10.3109/10717544.2013.779332.
   PubMed Web of Science ®Google Scholar
• Namdev S, Gujar K, Mandlik S, et al. Preparation and in vivo characterization of niosomal carriers of the antidiabetic drug repaglinide. PCI-Approved-IJPSN. 2015;8(1):2756–2767. doi: 10.37285/ijpsn.2015.8.1.8.
   Google Scholar
• Labieniec-Watala M, Przygodzki T, Sebekova K, et al. Can metabolic impairments in experimental diabetes be cured with poly (amido) amine (PAMAM) G4 dendrimers?–in the search for minimizing the adverse effects of PAMAM administration. Int J Pharm. 2014;464(1–2):152–167. doi: 10.1016/j.ijpharm.2014.01.011.
   PubMedGoogle Scholar
• Dong Z, Hamid KA, Gao Y, et al. Polyamidoamine dendrimers can improve the pulmonary absorption of insulin and calcitonin in rats. J Pharm Sci. 2011;100(5):1866–1878. doi: 10.1002/jps.22428.
   PubMed Web of Science ®Google Scholar
• Fang X, Yang T, Wang L, et al. Nano-cage-mediated refolding of insulin by PEG-PE micelle. Biomaterials. 2016;77:139–148. doi: 10.1016/j.biomaterials.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Li X, Wu W, Li J. Glucose-responsive micelles for insulin release. J Control Release. 2015;213:e122–e123. doi: 10.1016/j.jconrel.2015.05.206.
   PubMed Web of Science ®Google Scholar
• Damgé C, Socha M, Ubrich N, et al. Poly (ε-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J Pharm Sci. 2010;99(2):879–889. doi: 10.1002/jps.21874.
   PubMed Web of Science ®Google Scholar
• Salvioni L, Fiandra L, Del Curto MD, et al. Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats. Pharmacol Res. 2016;110:122–130. doi: 10.1016/j.phrs.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Andreani T, Silva AM, Souto EB. Silica-based matrices: state of the art and new perspectives for therapeutic drug delivery. Biotechnol Appl Biochem. 2015;62(6):754–764. doi: 10.1002/bab.1322.
   PubMed Web of Science ®Google Scholar
• He H, Ye J, Sheng J, et al. Overcoming oral insulin delivery barriers: application of cell-penetrating peptide and silica-based nanoporous composites. Front Chem Sci Eng. 2013;7(1):9–19. doi: 10.1007/s11705-013-1306-9.
   Web of Science ®Google Scholar
• Doktorovova S, Kovačević AB, Garcia ML, et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235–252. doi: 10.1016/j.ejpb.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Fangueiro JF, Gonzalez-Mira E, Martins-Lopes P, et al. A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm Dev Technol. 2013;18(3):545–549. doi: 10.3109/10837450.2011.591804.
   PubMed Web of Science ®Google Scholar
• Severino P, Andreani T, Chaud VM, et al. Essential oils as active ingredients of lipid nanocarriers for chemotherapeutic use. Curr Pharm Biotechnol. 2015;16(4):365–370. doi: 10.2174/1389201016666150206111253.
   PubMed Web of Science ®Google Scholar
• Liu L, Tang Y, Gao C, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B Biointerf. 2014;115:125–131. doi: 10.1016/j.colsurfb.2013.11.029.
   PubMed Web of Science ®Google Scholar
• Alam M, Rizwanullah M, Mir SR, et al. Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis. OpenNano. 2023;10:100123. doi: 10.1016/j.onano.2023.100123.
   Google Scholar
• Zhang X, Qi J, Lu Y, et al. Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity. Nanoscale Res Lett. 2014;9(1):185. doi: 10.1186/1556-276X-9-185.
   PubMedGoogle Scholar
• Agrawal AK, Harde H, Thanki K, et al. Improved stability and antidiabetic potential of insulin-containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules. 2014;15(1):350–360. doi: 10.1021/bm401580k.
   PubMed Web of Science ®Google Scholar
• Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441(1–2):693–700. doi: 10.1016/j.ijpharm.2012.10.025.
   PubMed Web of Science ®Google Scholar
• Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size, and administered dose. Eur J Pharm Biopharm. 2012;81(2):265–272. doi: 10.1016/j.ejpb.2012.02.009.
   PubMed Web of Science ®Google Scholar
• Mazayen ZM, Ghoneim AM, Elbatanony RS, et al. Pharmaceutical nanotechnology: from the bench to the market. Futur J Pharm Sci. 2022;8(1):12. doi: 10.1186/s43094-022-00400-0.
   PubMed Web of Science ®Google Scholar
• Li X, Qi J, Xie Y, et al. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats. Int J Nanomedicine. 2013;8:23–32. doi: 10.2147/IJN.S38507.
   PubMed Web of Science ®Google Scholar
• Vaculikova E, Pokorna A, Placha D, et al. Improvement of glibenclamide water solubility by nanoparticle preparation. J Nanosci Nanotechnol. 2019;19(5):3031–3034. doi: 10.1166/jnn.2019.15876.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu J, Zhou Q, et al. Berberine nanosuspension enhances hypoglycemic efficacy in streptozotocin-induced diabetic C57BL/6 mice. Evid Based Complement Alternat Med. 2015;2015:239749. doi: 10.1155/2015/239749.
   PubMed Web of Science ®Google Scholar